Imatinib mesylate-resistant cells were present in a man with chronic myeloid leukaemia (CML) before treatment with the drug

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1390, 2003-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 1, 2005-01 ,pp. : 89-91

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J   Xu G   Yu S   He L   Guo L  

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite

Imatinib mesylate normalised the bone marrow of patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

The use of imatinib appears to be associated with interstitial lung disease (ILD) in patients with chronic myeloid leukaemia (CML)

By  

Inpharma, Vol. 1, Iss. 1551, 2006-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite